medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2017, Number 5

<< Back Next >>

Ann Hepatol 2017; 16 (5)

Early Successes in an Open Access, Provincially Funded Hepatitis C Treatment Program in Prince Edward Island

Francheville JW, Rankin R, Beck J, Hoare C, Materniak S, German G, Barrett L, Bunimov-Wall N, Smyth D

Language: English
References: 24
Page: 749-758
PDF size: 185.24 Kb.


ABSTRACT

Introduction. The availability of curative hepatitis C therapies has created an opportunity to improve treatment delivery and access. Local providers, government, industry, and community groups in Prince Edward Island developed an innovative province-wide care model. Our goal was to describe the first year of program implementation. Material and methods. Using a communitybased prospective observational study design, all chronic hepatitis C referrals received from April 2015 to April 2016 were recorded in a database. Primary analysis assessed the time from referral to assessment/treatment, as well as the number of referrals, assessments, and treatment initiations. Secondary objectives included: 1) treatment effectiveness using intention-to-treat analysis; and 2) patient treatment experience assessed using demographics, adverse events, and medication adherence. Results. During the study period 242 referrals were received, 123 patients were seen for intake assessments, and 93 initiated direct-acting antiviral therapy based on medical need. This is compared to 4 treatment initiations in the previous 2 years. The median time from assessment to treatment initiation was 3 weeks. Eighty-two of 84 (97.6%, 95% CI 91.7 - 99.7%) patients for whom outcome data were available achieved sustained virologic response at 12 weeks post-treatment; 1 was lost to follow-up and 1 died from an unrelated event. In the voluntary registry, 39.7% of patients reported missed treatment doses. Conclusion. In conclusion, results from the first 12 months of this multi-phase hepatitis C elimination strategy demonstrate improved access to treatment, and high rates of safe engagement and cure for patients living with chronic hepatitis C genotype 1 infections.


REFERENCES

  1. Lee J, Conniff J, Kraus C, Schrager S. A brief clinical update on hepatitis C - The essentials. Wisc Med J 2015; 114: 263-9.

  2. Moorman AC, Gordon SC, Rupp LB, Spradling PR, Teshale EH, Lu M, Nerenz DR, et al. Baseline characteristics and mortality among people in care for chronic viral hepatitis: The chronic hepatitis cohort study. Clin Infect Dis 2013; 56: 40-50.

  3. O’Leary JG, Lepe R, Davis GL. Indications for liver transplantation. Gastroenterology 2008; 134: 1764-76.

  4. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol and Hepatol 2010; 8: 280-8.e1.

  5. Morgan TR, Ghany MG, Kim H, Snow KK, Shiffman ML, De Santo JL, Lee WM, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010; 52: 833-44.

  6. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of allcause mortality in patients with hepatitis C. Clin Gastroenterol and Hepatol 2011; 9: 509-16.e1.

  7. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis c and advanced hepatic fibrosis. JAMA 2012; 308: 2584-93.

  8. MacParland SA, Bilodeau M, Grebely J, Bruneau J, Cooper C, Klein M, Sagan SM, et al. The 3rd Canadian Symposium on Hepatitis C Virus: Expanding care in the interferon-free era. Can J Gastroenterol and Hepatol 2014; 28: 481-7.

  9. Marshall AD, Saeed S, Barrett L, Cooper CL, Treloar C, Bruneau J, Feld JJ, et al. Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: A descriptive study. CMAJ Open 2016; 4: E605- E614.

  10. Barua S, Greenwald R, Grebely J, Dore GJ, Swan T, Taylor LE. Restrictions for medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med 2015; 163: 215-23.

  11. Martin NK, Vickerman P, Grebely J, Hellard M, Hutchinson SJ, Lima VD, Foster GR, et al. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 2013; 58: 1598-609.

  12. Hellard M, Rolls DA, Sacks-Davis R, Robins G, Pattison P, Higgs P, Aitken C, et al. The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs. Hepatology 2014; 60: 1861-70.

  13. Smyth DJ, Webster D, Barrett L, MacMillan M, McKnight L, Schweiger F. Transitioning to highly effective therapies for the treatment of chronic hepatitis C virus infection: A policy statement and implementation guideline. Can J Gastroenterol and Hepatol 2014; 28: 529-34.

  14. Statistics Canada. Census profile: Prince Edward Island, 2016 census. 2017. http://www12.statcan.gc.ca/census-recensement/ 2016/dp-pd/prof/index.cfm?Lang=E. Accessed June 13, 2017.

  15. Remis RS. Modelling the incidence and prevalence of hepatitis C infection and its sequelae in Canada, 2007: Final report. Public Health Agency of Canada 2007. Available at: http:// www.phac-aspc.gc.ca/sti-its-surv-epi/model/pdf/model07- eng.pdf. Accessed November 16, 2016.

  16. Myers RP, Shah H, Burak KW, Cooper C, Feld JJ. An update on the management of chronic hepatitis C: 2015 consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol and Hepatol 2015; 29: 19-34.

  17. De Ledinghen V, Vergniol J. Transient elastography (fibroscan). Gastroenterol Clin Biol 2008; 32: 58-67.

  18. Feld JJ, Jacobson IM, Hézode C, Asselah T, Ruane PJ, Gruener N, Abergel A, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 2015; 373: 2599-607.

  19. Foster GR, Afdhal N, Roberts SK, Bräu N, Gane EJ, Pianko S, Lawitz E, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 2015; 373: 2608-17.

  20. Leroy V, Angus P, Bronowicki J, Dore GJ, Hezode C, Pianko S, Pol S, et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3). Hepatology 2016; 63: 1430-41.

  21. Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourlier‘e M, Sulkowski MS, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. New Engl J Med 2014; 370: 1604-14.

  22. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, Weiland O, et al. Treatment of HCV with ABT-450/rombitasvir and dasabuvir with ribavirin. New Engl J Med 2014; 370: 1594-603.

  23. Dore G, Altice F, Litwin A, Dalgard O, Gane E, Shibolet O. CEDGE CO-STAR: Efficacy of grazoprevir/elbasvir fixed dose combination for 12 weeks in HCV-infected persons who inject drugs on opioid agonist therapy. Hepatology 2015; 62: 227A-228A.

  24. Lalezari J, Sullivan JG, Varunok P, Galen E, Kowdley KV, Rustgi V, Aguilar H, et al. Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. J Hepatol 2015; 63: 364-9.




2020     |     www.medigraphic.com